ArticleGastroenterology research and practice2012
Benefits from long-term treatment in irritable bowel syndrome.
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.International journal of colorectal disease · 2020Trial
- Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.World journal of gastroenterology · 2014Trial
- Remote Self-help cognitive-behavioural Therapy for irritable bowel syndrome (ReSeT): protocol for a randomised controlled trial.BMC gastroenterology · 2026Article
- Treatment of Irritable Bowel Syndrome With Antispasmolytics in Taiwan, Hong Kong, and Vietnam: A Delphi Expert Consensus Statement.Journal of neurogastroenterology and motility · 2025Article
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.Journal of clinical medicine · 2024Review
- Otilonium Bromide Prevents Cholinergic Changes in the Distal Colon Induced by Chronic Water Avoidance Stress, a Rat Model of Irritable Bowel Syndrome.International journal of molecular sciences · 2023Article
- Gwakhyangjeonggi-san for irritable bowel syndrome: A protocol for systematic review and meta-analysis.Medicine · 2021Article
- Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan.Frontiers in pharmacology · 2021Article
- Experimental Models of Irritable Bowel Syndrome and the Role of the Enteric Neurotransmission.Journal of clinical medicine · 2018Review
- Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.Journal of cellular and molecular medicine · 2017Article
- Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.Therapeutic advances in gastroenterology · 2017Article
- Role of antispasmodics in the treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.Clinical and experimental gastroenterology · 2014Review
- Article
- IBS and the role of otilonium bromide.International journal of colorectal disease · 2013Review
- Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.Gastroenterology research and practice · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is known that irritable bowel syndrome (IBS) is a chronic disease of cyclic nature characterized by recurrent symptoms. IBS patients should receive, as initial therapeutic approach a short course of treatment which, if effective, has the additional value of confirming the diagnosis. Long-term treatment should be reserved to diagnosed IBS patients with recurrent symptoms. Clinical trials with stabilized therapies and new active treatments showed an improvement of the symptoms over placebo that is often time-dependent but with high relapse rates (around 40%-50% when stopping treatment). Relapse is not always immediate after stopping treatment and the recent data from OBIS trial with otilonium bromide or with psychotherapy, showed that due to different chemico-physical characteristics of the drugs or the psychosomatic impact to the disease not all treatment gave the same relapsing rate if compared to placebo. Results of IBS clinical trials with different therapies tailored to the patient needs indicate that a cyclic treatment therapy is advisable to counteract the nature of the disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.